TruScreen Appoints Distributor to South Africa

NZX/ASX Announcement

4 November 2025

TruScreen appoints distributor to South Africa

• TruScreen appoints Johannesburg distributor AIR to distribute its AI enabled TruScreen cervical cancer screening system in South Africa
• South Africa has an extremely high cervical cancer mortality rate - 19.6 per 100,000, compared to New Zealand and Australia’s 1.7 per 100,000, with an estimated 10,702 new cases of cervical cancer each year and 5,807 deaths annually
• South Africa had the 10th highest global cervical cancer incidence in 2022
• South Africa has an estimated screening population of over 19 million women

TruScreen Group Limited (“TruScreen” or “the Company”) advises the appointment of South African medical products company AIR to distribute its unique AI enabled TruScreen cervical cancer screening system.

South Africa has an extremely high cervical cancer mortality rate - 19.6 per 100,000, compared to New Zealand and Australia’s 1.7 per 100,000 , with an estimated 10,702 new cases of cervical cancer each year and 5,807 deaths annually. South Africa had the 10th highest global cervical cancer incidence in 2022.

These statistics highlight persisting challenges South Africa faces with late diagnosis, limited screening coverage, and healthcare access. TruScreen, is a portable AI enabled, real-time, laboratory-free cervical cancer screening system that is ideally suited to meet these challenges.

The investigators of TruScreen’s most recently peer-reviewed study in Saudi Arabia concluded: “TruScreen represents a reliable, practical screening tool for cervical neoplasms and provides an evidence-based approach for policymakers when selecting the optimal cervical cancer screening strategy in countries without an established national screening program.

AIR will market and sell TruScreen in South Africa and will be supported by Evohealth, a Guateng-based manufacturer of pharmaceuticals and distributor of pharmacy products and medical devices. They will register and provide logistics support for TruScreen in South Africa.

Registration is expected to be completed in 3 months, with first sales expected to occur in January 2026.

South African distribution is a key market for TruScreen’s African strategy. TruScreen has major public screening programs to recommence in Zimbabwe, a proposed local Public Screening program (in planning) for Eswatini, and early commercial sales in Rwanda. The addition of 19 million women in South Africa will grow TruScreen’s African distribution reach to an addressable market of 30 million women.



TruScreen CEO, Martin Dillon commented:

“Adding South Africa is a major milestone in our African distribution strategy. The majority of African nations are emerging economies with limited or no screening laboratory infrastructure. The TruScreen technology will assist to reduce deaths from cervical cancer. TruScreen is also well suited to increase the screening rates in 47 WHO member nations looking to achieve 70% screening rates by 2030.”


This announcement has been approved by the Board.


Ends


For more information, visit www.truscreen.com or contact:
Martin Dillon
Chief Executive Officer
[email protected]
Guy Robertson
Chief Financial Officer
[email protected]

---

Announcement PDF